Pancreatic cancer is considered among the most aggressive and the least curable of all
human malignancies. It is usually characterized by multiple aberrations in tumor suppressor …

Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A
hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene …

The clear importance of mutated KRAS as a therapeutic target has driven the investigation of
multiple approaches to inhibit oncogenic KRAS signaling at different molecular levels …

Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer
has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS …

KRAS, a predominant member of the RAS family, is the most frequently mutated oncogene
in human pancreatic cancer (∼ 95% of cases). Mutations in KRAS lead to its constitutive …

Pancreatic cancer is a human malignancy with one of the highest mortality rates and little
progress has been achieved in its treatment in recent decades. Further improvement to the …

Opinion statement Since the discovery of oncogenes in the 1970s, cancer doctors and
researchers alike have understood the promise of discovering drugs to block the dominantly …

Mutational activation of the KRAS oncogene is found in~ 95% of pancreatic ductal
adenocarcinoma (PDAC), the major form of pancreatic cancer. With substantial experimental …

Abstract Kirsten Rat Sarcoma (KRAS) is a master oncogene involved in cellular proliferation
and survival and is the most commonly mutated oncogene in all cancers. Activating KRAS …

RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated oncogene
family in human cancer. With the highest RAS mutation frequencies seen with the top three …